Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | President and CEO | March 23, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date March 23, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,000 |
Reported balance
After 2026-03-23 transaction · row 1
1 source rowRow 1 · 2026-03-23 · Exercise / conversion · Acquired 120,000 · Balance 190,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2033-05-05 | Direct | 237,165 |
Reported balance
After 2026-03-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-23 · Exercise / conversion · Disposed 120,000 · Balance 237,165 F1: Options to purchase 89,291 shares vest on 5/5/24 and options to purchase 267,874 shares vest quarterly in 12 equal amounts commencing on 8/5/24. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2034-05-14 | Direct | 10,406 |
Reported balance
Holding disclosure · report date 2026-03-23 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 10,406 F2: Options to purchase 2,601 shares vest on 5/14/25 and options to purchase the remaining 7,805 shares vest quarterly in 12 equal amounts commencing on 8/14/25. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 89,291 shares vest on 5/5/24 and options to purchase 267,874 shares vest quarterly in 12 equal amounts commencing on 8/5/24.
F2: Options to purchase 2,601 shares vest on 5/14/25 and options to purchase the remaining 7,805 shares vest quarterly in 12 equal amounts commencing on 8/14/25.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 25, 2026 20:54 UTC | NEPHROS INC NEPH · Entity 7279 | Exercise / conversionStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0000914190-26-000053 · form4.xml · derivative · entry 2 Banks Robert R. Jr. · CIK 0001977237 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,165 Underlying: Common Stock · 120,000 shares Expires 2033-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options to purchase 89,291 shares vest on 5/5/24 and options to purchase 267,874 shares vest quarterly in 12 equal amounts commencing on 8/5/24. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 20:54 UTC | NEPHROS INC NEPH · Entity 7279 | Exercise / conversionCommon Stock | 120,000 | $1.44 | $172,800.00 |
DisclosureSEC source: 0000914190-26-000053 · form4.xml · nonDerivative · entry 1 Banks Robert R. Jr. · CIK 0001977237 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 16, 2024 20:49 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 50,000 | $2.24 | $112,050.00 |
DisclosureSEC source: 0001062993-24-010486 · form4.xml · nonDerivative · entry 1 Banks Robert R. Jr. · CIK 0001977237 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.10 to $2.25, inclusive. The reporting person undertakes to provide Nephros Inc., any security holder of Nephros Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the set range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:49 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 10,406 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001062993-24-010486 · form4.xml · derivative · entry 3 Banks Robert R. Jr. · CIK 0001977237 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,406 Underlying: Common Stock · 10,406 shares Expires 2034-05-14 F3 · derivative.exercise_date: Options to purchase 2,601 shares vest on 5/14/25 and options to purchase the remaining 7,805 shares vest quarterly in 12 equal amounts commencing on 8/14/25. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:17 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 18,000 | $2.20 | $39,646.80 |
DisclosureSEC source: 0001062993-23-022326 · form4.xml · nonDerivative · entry 1 Banks Robert R. Jr. · CIK 0001977237 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| August 15, 2023 Filed Aug 15, 2023 20:15 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 1,901 | $1.69 | $3,206.80 |
DisclosureSEC source: 0001062993-23-016523 · form4.xml · nonDerivative · entry 2 Banks Robert R. Jr. · CIK 0001977237 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.66 to $1.73, inclusive. The reporting person undertakes to provide Nephros Inc., any security holder of Nephros Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the set range set forth in this footnote. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:15 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 99 | $1.50 | $148.50 |
DisclosureSEC source: 0001062993-23-016523 · form4.xml · nonDerivative · entry 1 Banks Robert R. Jr. · CIK 0001977237 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.